Who Paid My Doc
Seon Lee
Hospice and Palliative Medicine Temple Terrace, FL Medical Doctor
NPI 1225492416 CMS profile 8332317
12470 Telecom Dr Ste 300W, Temple Terrace, FL 33637
General payments
$129
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Seon Lee of Temple Terrace, FL is reported in the CMS Open Payments database as having received $129 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $129 | 1 |
Beside peers
- Seon Lee
- Hospice and Palliative Medicine median
- Middle half of Hospice and Palliative Medicine
- National median
In program year 2025, general payments to Seon Lee were reported at $0. Among 28 Hospice and Palliative Medicine profiles paid that year, the median was $51 and the middle half received between $23 and $108.
Show as a table
| Year | Seon Lee | Hospice and Palliative Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $80 | $34–$149 | $163 |
| 2020 | $0 | $35 | $16–$125 | $114 |
| 2021 | $0 | — | — | $132 |
| 2022 | $129 | $54 | $29–$126 | $149 |
| 2023 | $0 | $50 | $24–$125 | $160 |
| 2024 | $0 | $34 | $25–$65 | $164 |
| 2025 | $0 | $51 | $23–$108 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
88
Drug cost
$8,184
Branded share of claims
13.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 12 | $7,137 | |
| Morphine Sulfate | Generic | 21 | $528 | |
| Lorazepam | Generic | 11 | $192 | |
| Losartan Potassium | Generic | 17 | $180 | |
| Amlodipine Besylate | Generic | 12 | $94 | |
| Atorvastatin Calcium | Generic | 15 | $54 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hospice and Palliative Medicine in Florida
Andrew Sy
Hospice and Palliative Medicine · Miami, FL
Rachel Fisher
Hospice and Palliative Medicine · Orlando, FL
Amanda Bashir
Hospice and Palliative Medicine · St Petersburg, FL
Amisha Desai
Hospice and Palliative Medicine · Hollywood, FL
Michelle Hidalgo
Hospice and Palliative Medicine · Orlando, FL
Blaine Pitts
Hospice and Palliative Medicine · Orlando, FL
Related records
Hospice and Palliative Medicine in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Hospice and Palliative Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.